Clinical trials: First Progression of Glioblastoma
Glioblastoma Multiforme
Convection Enhanced Localized Administration of PRX321 With Real-time Imaging for Therapy of Recurrent Glioblastoma (CLARITY-1)
A Phase II, multi-center, open-label, single-arm study in up to 42 subjects with first recurrence or progression of GBM at up to 12 sites in Australia, Europe, Israel, and the United States.
- Trial name
- CLARITY-1 (NCT00797940)
- Testing
- IL-4PE
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sophiris Bio Corp
Glioblastoma
A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma
This multicenter, double-blind, placebo-controlled, randomized study will evaluate the efficacy and safety of the addition of bevacizumab treatment to lomustine (in 2nd-line [2L] treatment) and SOC (in 3rd-line [3L] and…
- Trial name
- NCT01860638
- Testing
- Bevacizumab, Lomustine, Radiotherapy
- Where
- 64 sites in Austria, Bulgaria and 13 more
- Volunteers
- 296 people
- Sponsor
- Hoffmann-La Roche
Glioblastoma (GBM)
A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of STAR-001 (LP-184) in Combination With Spironolactone in Supratentorial Glioblastoma at First Progression
Approximately 58-68 total subjects will be enrolled. In the first stage, 10 response evaluable subjects (either IDHwt or IDHm Grade 4 astrocytoma) will be enrolled.
- Trial name
- NCT07431216
- Testing
- STAR-001 (LP-184) will be administered via IV infusion over 30 (± 5) minutes on Day 1 and Day 8 of each 21-day cycle., Spironolactone (drug)
- Volunteers
- 68 people
- Sponsor
- Starlight Therapeutics Inc.
Glioblastoma Multiforme
APG101 in Glioblastoma
This is a phase II study of APG101 + reirradiation (RT) versus reirradiation. Patients suffering from a malignant brain tumor called glioblastoma having a first or second progression can be included.
- Trial name
- NCT01071837
- Testing
- APG101, Blood drawing
- Where
- 21 sites in Austria, Germany
- Volunteers
- 84 people
- Sponsor
- Apogenix GmbH
Glioblastoma
Safety and Efficacy of Different Administration Sequences of L19TNF With Lomustine in Glioblastoma at First Progression
Open label phase I study in subjects with glioblastoma at first progression to explore two different administration schedules of lomustine for the combination with L19TNF (ARM 1 and ARM 2).
- Trial name
- GLIOASTRA (NCT05304663)
- Testing
- Onfekafusp alfa, Lomustine
- Sponsor
- Philogen S.p.A.
Glioblastoma
A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression
Glioblastomas are the most common and most aggressive primary brain tumors in adults. The prognosis is poor despite multimodal therapy with surgery, radiotherapy and chemotherapy. Therefore, novel treatments are urgently needed.
- Trial name
- GLIOSTAR (NCT04573192)
- Testing
- L19TNF, Lomustine
- Where
- 15 sites in France, Germany and 2 more
- Volunteers
- 142 people
- Sponsor
- Philogen S.p.A.